Do analysts prefer PPBT or OSRH?

Purple Biotech presently has a consensus price target of $30.00, indicating a potential upside of 1,947.78%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than OSR. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PPBT or OSRH more profitable?

Purple Biotech has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -147.77% -111.59% OSR -593.15% -8.36% -6.24%

Do analysts rate PPBT or CDIO?

Purple Biotech presently has a consensus price target of $30.00, indicating a potential upside of 1,947.78%. Given Purple Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Purple Biotech is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor PPBT or CDIO?

In the previous week, Purple Biotech and Purple Biotech both had 1 articles in the media. Cardio Diagnostics' average media sentiment score of 0.84 beat Purple Biotech's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Purple Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardio Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend PPBT or AQB?

Purple Biotech currently has a consensus price target of $30.00, indicating a potential upside of 1,947.78%. Given Purple Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Purple Biotech is more favorable than AquaBounty Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AquaBounty Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PPBT or AQB?

AquaBounty Technologies is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Purple Biotech N/A N/A -$26.39M -$23.25 N/A AquaBounty Technologies N/A N/A -$18.49M -$0.82 N/A

Is PPBT or AQB more profitable?

AquaBounty Technologies' return on equity of -147.07% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -147.77% -111.59% AquaBounty Technologies N/A -147.07% -28.73%

Does the media prefer PPBT or AQB?

In the previous week, AquaBounty Technologies had 1 more articles in the media than Purple Biotech. MarketBeat recorded 2 mentions for AquaBounty Technologies and 1 mentions for Purple Biotech. AquaBounty Technologies' average media sentiment score of 0.59 beat Purple Biotech's score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Purple Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral AquaBounty Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CELZ or PPBT?

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 1,947.78%. Given Purple Biotech's higher probable upside, analysts clearly believe Purple Biotech is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is CELZ or PPBT more profitable?

Creative Medical Technology's return on equity of -86.52% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -86.52% -81.96% Purple Biotech N/A -147.77% -111.59%

Does the media refer more to CELZ or PPBT?

In the previous week, Creative Medical Technology had 1 more articles in the media than Purple Biotech. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Purple Biotech. Creative Medical Technology's average media sentiment score of 0.57 beat Purple Biotech's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Creative Medical Technology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Purple Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate XTLB or PPBT?

Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 1,947.78%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, XTLB or PPBT?

XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XTL Biopharmaceuticals N/A N/A -$6.97M -$0.64 N/A Purple Biotech N/A N/A -$26.39M -$23.25 N/A

Is XTLB or PPBT more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets XTL Biopharmaceuticals N/A N/A N/A Purple Biotech N/A -147.77% -111.59%

Purple Biotech (PPBT) Competitors

$1.46 +0.03 (+1.74%)

As of 01:44 PM Eastern

Compare

PPBT vs. OSRH, CDIO, AQB, CELZ, and XTLB

Should you buy Purple Biotech stock or one of its competitors? Purple Biotech's main competitors and comparable companies include OSR (OSRH), Cardio Diagnostics (CDIO), AquaBounty Technologies (AQB), Creative Medical Technology (CELZ), and XTL Biopharmaceuticals (XTLB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Purple Biotech compare to OSR?

Purple Biotech (NASDAQ:PPBT) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

In the previous week, Purple Biotech had 1 more articles in the media than OSR. MarketBeat recorded 1 mentions for Purple Biotech and 0 mentions for OSR. Purple Biotech's average media sentiment score of 0.00 equaled OSR'saverage media sentiment score.

Company	Overall Sentiment
Purple Biotech	Neutral
OSR	Neutral

Purple Biotech presently has a consensus price target of $30.00, indicating a potential upside of 1,947.78%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Purple Biotech is more favorable than OSR.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 3.0% of Purple Biotech shares are held by insiders. Comparatively, 36.9% of OSR shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Purple Biotech has higher earnings, but lower revenue than OSR. OSR is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A
OSR	$1.81M	4.66	-$27.06M	-$0.37	N/A

Purple Biotech has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, OSR has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market.

Purple Biotech has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-147.77%	-111.59%
OSR	-593.15%	-8.36%	-6.24%

Summary

Purple Biotech beats OSR on 8 of the 14 factors compared between the two stocks.

How does Purple Biotech compare to Cardio Diagnostics?

Purple Biotech (NASDAQ:PPBT) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Purple Biotech has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.28, suggesting that its stock price is 128% more volatile than the broader market.

Cardio Diagnostics has higher revenue and earnings than Purple Biotech. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A
Cardio Diagnostics	$14.45K	401.49	-$6.50M	-$2.92	N/A

Purple Biotech presently has a consensus price target of $30.00, indicating a potential upside of 1,947.78%. Given Purple Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Purple Biotech is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

9.6% of Purple Biotech shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 3.0% of Purple Biotech shares are held by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Purple Biotech has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Cardio Diagnostics' return on equity of -82.28% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-147.77%	-111.59%
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

In the previous week, Purple Biotech and Purple Biotech both had 1 articles in the media. Cardio Diagnostics' average media sentiment score of 0.84 beat Purple Biotech's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cardio Diagnostics beats Purple Biotech on 8 of the 14 factors compared between the two stocks.

How does Purple Biotech compare to AquaBounty Technologies?

Purple Biotech (NASDAQ:PPBT) and AquaBounty Technologies (NASDAQ:AQB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Purple Biotech currently has a consensus price target of $30.00, indicating a potential upside of 1,947.78%. Given Purple Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Purple Biotech is more favorable than AquaBounty Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AquaBounty Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

AquaBounty Technologies' return on equity of -147.07% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-147.77%	-111.59%
AquaBounty Technologies	N/A	-147.07%	-28.73%

In the previous week, AquaBounty Technologies had 1 more articles in the media than Purple Biotech. MarketBeat recorded 2 mentions for AquaBounty Technologies and 1 mentions for Purple Biotech. AquaBounty Technologies' average media sentiment score of 0.59 beat Purple Biotech's score of 0.00 indicating that AquaBounty Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AquaBounty Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AquaBounty Technologies is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A
AquaBounty Technologies	N/A	N/A	-$18.49M	-$0.82	N/A

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 8.9% of AquaBounty Technologies shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 1.0% of AquaBounty Technologies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Purple Biotech has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. Comparatively, AquaBounty Technologies has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

Summary

AquaBounty Technologies beats Purple Biotech on 7 of the 13 factors compared between the two stocks.

How does Purple Biotech compare to Creative Medical Technology?

Creative Medical Technology (NASDAQ:CELZ) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Creative Medical Technology has higher revenue and earnings than Purple Biotech. Creative Medical Technology is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	635.28	-$5.99M	-$2.07	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

1.4% of Creative Medical Technology shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 1.0% of Creative Medical Technology shares are owned by company insiders. Comparatively, 3.0% of Purple Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Purple Biotech has a consensus price target of $30.00, suggesting a potential upside of 1,947.78%. Given Purple Biotech's higher probable upside, analysts clearly believe Purple Biotech is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Creative Medical Technology has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market.

In the previous week, Creative Medical Technology had 1 more articles in the media than Purple Biotech. MarketBeat recorded 2 mentions for Creative Medical Technology and 1 mentions for Purple Biotech. Creative Medical Technology's average media sentiment score of 0.57 beat Purple Biotech's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Creative Medical Technology	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Purple Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Creative Medical Technology's return on equity of -86.52% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
Purple Biotech	N/A	-147.77%	-111.59%

Summary

Creative Medical Technology beats Purple Biotech on 8 of the 12 factors compared between the two stocks.

How does Purple Biotech compare to XTL Biopharmaceuticals?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Purple Biotech (NASDAQ:PPBT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

XTL Biopharmaceuticals has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Purple Biotech has a beta of 0.71, meaning that its stock price is 29% less volatile than the broader market.

Purple Biotech has a consensus price target of $30.00, indicating a potential upside of 1,947.78%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Purple Biotech shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 3.0% of Purple Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Purple Biotech had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 1 mentions for Purple Biotech and 0 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 0.00 equaled Purple Biotech'saverage media sentiment score.

Company	Overall Sentiment
XTL Biopharmaceuticals	Neutral
Purple Biotech	Neutral

XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	N/A	N/A	-$6.97M	-$0.64	N/A
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A

XTL Biopharmaceuticals' return on equity of 0.00% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Purple Biotech	N/A	-147.77%	-111.59%

Summary

XTL Biopharmaceuticals and Purple Biotech tied by winning 6 of the 12 factors compared between the two stocks.

Get Purple Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PPBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PPBT vs. The Competition

Export

Metric	Purple Biotech	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.36M	$3.91B	$7.25B	$13.20B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-0.06	14.11	275.22	25.75
Price / Sales	N/A	1,581.70	693.67	103.18
Price / Cash	N/A	41.62	28.04	34.72
Price / Book	0.14	15.63	10.57	6.35
Net Income	-$26.39M	-$22.86M	$3.49B	$358.31M
7 Day Performance	-16.76%	-1.34%	-0.20%	0.58%
1 Month Performance	-6.69%	-4.58%	-2.68%	-2.85%
1 Year Performance	-74.87%	37.94%	18.19%	6.00%

Purple Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PPBT Purple Biotech	2.0276 of 5 stars	$1.47 +1.7%	$30.00 +1,947.8%	-75.3%	$1.36M	N/A	N/A	10	News Coverage Analyst Downgrade
OSRH OSR	0.2586 of 5 stars	$0.18 -4.4%	N/A	-70.9%	$6.22M	$1.81M	N/A	N/A	Gap Down
CDIO Cardio Diagnostics	1.024 of 5 stars	$2.00 -3.4%	N/A	-49.4%	$6.13M	$10K	N/A	1	Positive News Gap Up
AQB AquaBounty Technologies	0.7136 of 5 stars	$1.10 -4.3%	N/A	-26.0%	$5.92M	$2.47M	N/A	100
CELZ Creative Medical Technology	1.4093 of 5 stars	$0.89 +0.8%	N/A	-72.5%	$5.79M	$10K	N/A	5	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PPBT) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Purple Biotech (PPBT) Competitors

PPBT vs. OSRH, CDIO, AQB, CELZ, and XTLB

How does Purple Biotech compare to OSR?

Summary

How does Purple Biotech compare to Cardio Diagnostics?

Summary

How does Purple Biotech compare to AquaBounty Technologies?

Summary

How does Purple Biotech compare to Creative Medical Technology?

Summary

How does Purple Biotech compare to XTL Biopharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Purple Biotech (PPBT) Competitors

PPBT vs. OSRH, CDIO, AQB, CELZ, and XTLB

How does Purple Biotech compare to OSR?

Does the media prefer PPBT or OSRH?

Do analysts prefer PPBT or OSRH?

Do insiders & institutionals believe in PPBT or OSRH?

Which has higher earnings & valuation, PPBT or OSRH?

Which has more volatility & risk, PPBT or OSRH?

Is PPBT or OSRH more profitable?

Summary

How does Purple Biotech compare to Cardio Diagnostics?

Which has more volatility and risk, PPBT or CDIO?

Which has stronger valuation and earnings, PPBT or CDIO?

Do analysts rate PPBT or CDIO?

Do institutionals & insiders have more ownership in PPBT or CDIO?

Is PPBT or CDIO more profitable?

Does the media favor PPBT or CDIO?

Summary

How does Purple Biotech compare to AquaBounty Technologies?

Do analysts recommend PPBT or AQB?

Is PPBT or AQB more profitable?

Does the media prefer PPBT or AQB?

Which has stronger earnings & valuation, PPBT or AQB?

Do institutionals & insiders believe in PPBT or AQB?

Which has more volatility and risk, PPBT or AQB?

Summary

How does Purple Biotech compare to Creative Medical Technology?

Which has higher earnings & valuation, CELZ or PPBT?

Do insiders & institutionals hold more shares of CELZ or PPBT?

Do analysts recommend CELZ or PPBT?

Which has more risk and volatility, CELZ or PPBT?

Does the media refer more to CELZ or PPBT?

Is CELZ or PPBT more profitable?

Summary

How does Purple Biotech compare to XTL Biopharmaceuticals?

Which has more risk and volatility, XTLB or PPBT?

Do analysts rate XTLB or PPBT?

Do insiders and institutionals believe in XTLB or PPBT?

Does the media favor XTLB or PPBT?

Which has preferable valuation & earnings, XTLB or PPBT?

Is XTLB or PPBT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PPBT vs. The Competition

Purple Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools